<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">41010364</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-1729</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>10</Day></PubDate></JournalIssue><Title>Life (Basel, Switzerland)</Title><ISOAbbreviation>Life (Basel)</ISOAbbreviation></Journal><ArticleTitle>GLP-1 Receptor Agonists in Mood Disorders: A Psychiatric Perspective.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1422</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/life15091422</ELocationID><Abstract><AbstractText>Mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD), are among the leading causes of disability worldwide and are frequently associated with treatment resistance, functional impairment, and high comorbidity with metabolic dysfunction. Increasing evidence implicates insulin resistance (IR) as a key pathophysiological factor linking metabolic and psychiatric illness. IR is associated with chronic low-grade inflammation, hypothalamic-pituitary-adrenal (HPA) axis dysregulation, impaired neuroplasticity, mitochondrial dysfunction, and altered reward processing mechanisms that may contribute to core depressive features such as anhedonia, cognitive slowing, and emotional dysregulation. These processes are further exacerbated by the metabolic side effects of many psychotropic medications, creating a self-perpetuating cycle that worsens both psychiatric and physical health outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially developed for type 2 diabetes and obesity, have emerged as promising candidates to address this metabolic-psychiatric interface. Beyond improving glycemic control and promoting weight loss, GLP-1 RAs exert central actions relevant to mood disorders, including modulation of dopaminergic reward pathways, enhancement of hippocampal neurogenesis, attenuation of neuroinflammation, and regulation of appetite and energy balance. Preclinical studies demonstrate that GLP-1 RAs reduce microglial activation, promote hippocampal neurogenesis, and normalize stress-induced behavioral changes. Early clinical trials in patients with metabolic disorders suggest improvements in depressive symptoms, quality of life, and cognitive function, with some effects independent of weight loss or glycemic outcomes. Observational evidence also indicates reduced antidepressant use and psychological distress in diabetic and obese populations receiving GLP-1 RAs. While these findings are promising, large randomized controlled trials in primary psychiatric populations are lacking. Key challenges include clarifying dose-response relationships, disentangling central from peripheral effects, and addressing safety and adherence concerns in individuals with comorbid psychiatric conditions. Future research should focus on biomarker-informed stratification, comparative trials with standard treatments, and integration of GLP-1 RAs into multimodal care frameworks. Overall, GLP-1 RAs represent a biologically plausible and clinically relevant approach to bridging metabolic and psychiatric care, with the potential to improve outcomes in patients with mood disorders who carry a high metabolic burden.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carmellini</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-8130-4388</Identifier><AffiliationInfo><Affiliation>Department of Molecular and Developmental Medicine, Division of Psychiatry, School of Medicine, University of Siena, 53100 Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuomo</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular and Developmental Medicine, Division of Psychiatry, School of Medicine, University of Siena, 53100 Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rescalli</LastName><ForeName>Maria Beatrice</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Molecular and Developmental Medicine, Division of Psychiatry, School of Medicine, University of Siena, 53100 Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagiolini</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5827-0853</Identifier><AffiliationInfo><Affiliation>Department of Molecular and Developmental Medicine, Division of Psychiatry, School of Medicine, University of Siena, 53100 Siena, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Life (Basel)</MedlineTA><NlmUniqueID>101580444</NlmUniqueID><ISSNLinking>2075-1729</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">GLP-1 receptor agonists</Keyword><Keyword MajorTopicYN="N">insulin resistance</Keyword><Keyword MajorTopicYN="N">mood disorders</Keyword><Keyword MajorTopicYN="N">personalized psychiatry</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>1</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41010364</ArticleId><ArticleId IdType="pmc">PMC12471315</ArticleId><ArticleId IdType="doi">10.3390/life15091422</ArticleId><ArticleId IdType="pii">life15091422</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>The Lancet Psychiatry Global Burden of Disease 2021: Mental health messages. Lancet Psychiatry. 2024;11:573. doi: 10.1016/S2215-0366(24)00222-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(24)00222-0</ArticleId><ArticleId IdType="pubmed">39025623</ArticleId></ArticleIdList></Reference><Reference><Citation>Krupa A.J., Dudek D., Siwek M. Consolidating evidence on the role of insulin resistance in major depressive disorder. Curr. Opin. Psychiatry. 2024;37:23. doi: 10.1097/YCO.0000000000000905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YCO.0000000000000905</ArticleId><ArticleId IdType="pmc">PMC10715694</ArticleId><ArticleId IdType="pubmed">37972981</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntyre R.S., Alsuwaidan M., Baune B.T., Berk M., Demyttenaere K., Goldberg J.F., Gorwood P., Ho R., Kasper S., Kennedy S.H., et al. Treatment-resistant depression: Definition, prevalence, detection, management, and investigational interventions. World Psychiatry Off. J. World Psychiatr. Assoc. WPA. 2023;22:394&#x2013;412. doi: 10.1002/wps.21120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wps.21120</ArticleId><ArticleId IdType="pmc">PMC10503923</ArticleId><ArticleId IdType="pubmed">37713549</ArticleId></ArticleIdList></Reference><Reference><Citation>Calkin C., McClelland C., Cairns K., Kamintsky L., Friedman A. Insulin Resistance and Blood-Brain Barrier Dysfunction Underlie Neuroprogression in Bipolar Disorder. Front. Psychiatry. 2021;12:636174. doi: 10.3389/fpsyt.2021.636174.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2021.636174</ArticleId><ArticleId IdType="pmc">PMC8185298</ArticleId><ArticleId IdType="pubmed">34113269</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson K.T., Simard J.F., Henderson V.W., Nutkiewicz L., Lamers F., Nasca C., Rasgon N., Penninx B.W.J.H. Incident Major Depressive Disorder Predicted by Three Measures of Insulin Resistance: A Dutch Cohort Study. Am. J. Psychiatry. 2021;178:914&#x2013;920. doi: 10.1176/appi.ajp.2021.20101479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2021.20101479</ArticleId><ArticleId IdType="pubmed">34551583</ArticleId></ArticleIdList></Reference><Reference><Citation>Erichsen J.M., Fadel J.R., Reagan L.P. Peripheral versus central insulin and leptin resistance: Role in metabolic disorders, cognition, and neuropsychiatric diseases. Neuropharmacology. 2022;203:108877. doi: 10.1016/j.neuropharm.2021.108877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2021.108877</ArticleId><ArticleId IdType="pmc">PMC8642294</ArticleId><ArticleId IdType="pubmed">34762922</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#x103;lcudean A., Bodo C.-R., Popovici R.-A., Cozma M.-M., P&#x103;curar M., Cr&#x103;ciun R.-E., Crisan A.-I., Enatescu V.-R., Marinescu I., Cimpian D.-M., et al. Neuroinflammation&#x2014;A Crucial Factor in the Pathophysiology of Depression&#x2014;A Comprehensive Review. Biomolecules. 2025;15:502. doi: 10.3390/biom15040502.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom15040502</ArticleId><ArticleId IdType="pmc">PMC12024626</ArticleId><ArticleId IdType="pubmed">40305200</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.-K., Kim O.Y., Song J. Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function. Front. Pharmacol. 2020;11:1270. doi: 10.3389/fphar.2020.01270.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.01270</ArticleId><ArticleId IdType="pmc">PMC7456867</ArticleId><ArticleId IdType="pubmed">32922295</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanelli G., Bralten J., Franke B., Roth Mota N., Atti A.R., De Ronchi D., Monteleone A.M., Grassi L., Serretti A., Fabbri C., et al. Insulin resistance and poorer treatment outcomes in depression: Evidence from UK Biobank primary care data. Br. J. Psychiatry J. Ment. Sci. 2025:1&#x2013;10. doi: 10.1192/bjp.2025.82.</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.2025.82</ArticleId><ArticleId IdType="pubmed">40548411</ArticleId></ArticleIdList></Reference><Reference><Citation>Diz-Chaves Y., Herrera-P&#xe9;rez S., Gonz&#xe1;lez-Mat&#xed;as L.C., Lamas J.A., Mallo F. Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress. Nutrients. 2020;12:3304. doi: 10.3390/nu12113304.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12113304</ArticleId><ArticleId IdType="pmc">PMC7692797</ArticleId><ArticleId IdType="pubmed">33126672</ArticleId></ArticleIdList></Reference><Reference><Citation>Shomaker L.B., Tanofsky-Kraff M., Young-Hyman D., Han J.C., Yanoff L.B., Brady S.M., Yanovski S.Z., Yanovski J.A. Psychological symptoms and insulin sensitivity in adolescents. Pediatr. Diabetes. 2010;11:417&#x2013;423. doi: 10.1111/j.1399-5448.2009.00606.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-5448.2009.00606.x</ArticleId><ArticleId IdType="pmc">PMC2942090</ArticleId><ArticleId IdType="pubmed">19912553</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K., Li T., Yang T., Lin Y., Liao Y., Gan Z. Prevalence of insulin resistance and its associated factors in drug-na&#xef;ve patients with bipolar disorder among Han Chinese population. BMC Psychiatry. 2024;24:388. doi: 10.1186/s12888-024-05838-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-024-05838-5</ArticleId><ArticleId IdType="pmc">PMC11112952</ArticleId><ArticleId IdType="pubmed">38783222</ArticleId></ArticleIdList></Reference><Reference><Citation>Sep&#xfa;lveda-Lizcano L., Arenas-Villamizar V.V., Jaimes-Duarte E.B., Garc&#xed;a-Pacheco H., Paredes C.S., Berm&#xfa;dez V., Rivera-Porras D. Metabolic Adverse Effects of Psychotropic Drug Therapy: A Systematic Review. Eur. J. Investig. Health Psychol. Educ. 2023;13:1505&#x2013;1520. doi: 10.3390/ejihpe13080110.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ejihpe13080110</ArticleId><ArticleId IdType="pmc">PMC10453914</ArticleId><ArticleId IdType="pubmed">37623307</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan M.M., Khan Z.A., Khan M.A. Metabolic complications of psychotropic medications in psychiatric disorders: Emerging role of de novo lipogenesis and therapeutic consideration. World J. Psychiatry. 2024;14:767. doi: 10.5498/wjp.v14.i6.767.</Citation><ArticleIdList><ArticleId IdType="doi">10.5498/wjp.v14.i6.767</ArticleId><ArticleId IdType="pmc">PMC11230099</ArticleId><ArticleId IdType="pubmed">38984346</ArticleId></ArticleIdList></Reference><Reference><Citation>Meshkat S., Luciano C., Swiderski A., Li G., Aguilar R., Dunkley B., Reichelt A., Zhang Y., Greenshaw A., Vermetten E., et al. Efficacy and Safety of Glucagon-Like Peptide-1 Agonists for Psychiatric Symptoms: A Systematic Review. Brain Behav. 2025;15:e70661. doi: 10.1002/brb3.70661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.70661</ArticleId><ArticleId IdType="pmc">PMC12241715</ArticleId><ArticleId IdType="pubmed">40635383</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X., Wang M., Wen Z., Lu Z., Cui L., Fu C., Xue H., Liu Y., Zhang Y. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front. Endocrinol. 2021;12:721135. doi: 10.3389/fendo.2021.721135.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2021.721135</ArticleId><ArticleId IdType="pmc">PMC8419463</ArticleId><ArticleId IdType="pubmed">34497589</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z., Zong Y., Ma Y., Tian Y., Pang Y., Zhang C., Gao J. Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy. Signal Transduct. Target. Ther. 2024;9:234. doi: 10.1038/s41392-024-01931-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-024-01931-z</ArticleId><ArticleId IdType="pmc">PMC11408715</ArticleId><ArticleId IdType="pubmed">39289339</ArticleId></ArticleIdList></Reference><Reference><Citation>Breit S., Hubl D. The effect of GLP-1RAs on mental health and psychotropics-induced metabolic disorders: A systematic review. Psychoneuroendocrinology. 2025;176:107415. doi: 10.1016/j.psyneuen.2025.107415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2025.107415</ArticleId><ArticleId IdType="pubmed">40138849</ArticleId></ArticleIdList></Reference><Reference><Citation>Tempia Valenta S., Nicastri A., Perazza F., Marcolini F., Beghelli V., Atti A., Petroni M. The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review. Curr. Treat. Options Psychiatry. 2024;11:310&#x2013;357. doi: 10.1007/s40501-024-00331-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40501-024-00331-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Gammoh O., Qnais E., Aljabali A.A.A., Hataet T., Alqudah A. Metabolic resilience: Liraglutide&#x2019;s potential in alleviating depressive symptoms. Mol. Biol. Rep. 2025;52:550. doi: 10.1007/s11033-025-10641-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-025-10641-w</ArticleId><ArticleId IdType="pmc">PMC12141419</ArticleId><ArticleId IdType="pubmed">40471368</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulton C.D., Pickup J.C., Ismail K. The link between depression and diabetes: The search for shared mechanisms. Lancet Diabetes Endocrinol. 2015;3:461&#x2013;471. doi: 10.1016/S2213-8587(15)00134-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(15)00134-5</ArticleId><ArticleId IdType="pubmed">25995124</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes B.S., Salagre E., Enduru N., Grande I., Vieta E., Zhao Z. Insulin resistance in depression: A large meta-analysis of metabolic parameters and variation. Neurosci. Biobehav. Rev. 2022;139:104758. doi: 10.1016/j.neubiorev.2022.104758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2022.104758</ArticleId><ArticleId IdType="pmc">PMC11056930</ArticleId><ArticleId IdType="pubmed">35777578</ArticleId></ArticleIdList></Reference><Reference><Citation>Trammell T.S., Henderson N.L., Madkour H.S., Stanwood G.D., Graham D.L. GLP-1R activation alters performance in cognitive tasks in a sex-dependent manner. Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. 2021;42:2911&#x2013;2919. doi: 10.1007/s10072-020-04910-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04910-8</ArticleId><ArticleId IdType="pmc">PMC8140064</ArticleId><ArticleId IdType="pubmed">33222103</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderberg R., Richard J., Eerola K., Ferreras L., Nordbeck E., Hansson C., Nissbrandt H., Bergquist F., Gribble F., Reimann F., et al. Glucagon-Like Peptide 1 and Its Analogs Act in the Dorsal Raphe and Modulate Central Serotonin to Reduce Appetite and Body Weight. Diabetes. 2017;66:1062&#x2013;1073. doi: 10.2337/db16-0755.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db16-0755</ArticleId><ArticleId IdType="pmc">PMC6237271</ArticleId><ArticleId IdType="pubmed">28057699</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamer J.A., Testani D., Mansur R.B., Lee Y., Subramaniapillai M., McIntyre R.S. Brain insulin resistance: A treatment target for cognitive impairment and anhedonia in depression. Exp. Neurol. 2019;315:1&#x2013;8. doi: 10.1016/j.expneurol.2019.01.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2019.01.016</ArticleId><ArticleId IdType="pubmed">30695707</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Du P., Bai B., Feng P., Lian X., H&#xf6;lscher C., Wang Y., Xue G. The GLP-1 receptor agonist liraglutide inhibits necroptosis and neuroinflammation in a mouse model of Parkinson&#x2019;s disease with diabetes co-morbidity. Front. Neurosci. 2025;19:1596506. doi: 10.3389/fnins.2025.1596506.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2025.1596506</ArticleId><ArticleId IdType="pmc">PMC12213772</ArticleId><ArticleId IdType="pubmed">40606832</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith J.A., Das A., Ray S.K., Banik N.L. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res. Bull. 2012;87:10&#x2013;20. doi: 10.1016/j.brainresbull.2011.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2011.10.004</ArticleId><ArticleId IdType="pmc">PMC9827422</ArticleId><ArticleId IdType="pubmed">22024597</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Roub A., Al Madhoun A., Akhter N., Thomas R., Miranda L., Jacob T., Al-Ozairi E., Al-Mulla F., Sindhu S., Ahmad R. IL-1&#x3b2; and TNF&#x3b1; Cooperativity in Regulating IL-6 Expression in Adipocytes Depends on CREB Binding and H3K14 Acetylation. Cells. 2021;10:3228. doi: 10.3390/cells10113228.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10113228</ArticleId><ArticleId IdType="pmc">PMC8619559</ArticleId><ArticleId IdType="pubmed">34831450</ArticleId></ArticleIdList></Reference><Reference><Citation>Moiz A., Filion K.B., Tsoukas M.A., Yu O.H., Peters T.M., Eisenberg M.J. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. Am. J. Med. 2025;138:934&#x2013;940. doi: 10.1016/j.amjmed.2025.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2025.01.021</ArticleId><ArticleId IdType="pubmed">39892489</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q.K. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front. Endocrinol. 2024;15:1431292. doi: 10.3389/fendo.2024.1431292.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2024.1431292</ArticleId><ArticleId IdType="pmc">PMC11304055</ArticleId><ArticleId IdType="pubmed">39114288</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosili P., Mkhize B.C., Sibiya N.H., Ngubane P.S., Khathi A. Review of the direct and indirect effects of hyperglycemia on the HPA axis in T2DM and the co-occurrence of depression. BMJ Open Diabetes Res. Care. 2024;12:e003218. doi: 10.1136/bmjdrc-2022-003218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjdrc-2022-003218</ArticleId><ArticleId IdType="pmc">PMC10900365</ArticleId><ArticleId IdType="pubmed">38413177</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarwar H., Rafiqi S.I., Ahmad S., Jinna S., Khan S.A., Karim T., Qureshi O., Zahid Z.A., Elhai J.D., Levine J.C., et al. Hyperinsulinemia Associated Depression. Clin. Med. Insights Endocrinol. Diabetes. 2022;15:11795514221090244. doi: 10.1177/11795514221090244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/11795514221090244</ArticleId><ArticleId IdType="pmc">PMC9039439</ArticleId><ArticleId IdType="pubmed">35494421</ArticleId></ArticleIdList></Reference><Reference><Citation>Milaneschi Y., Simmons W.K., van Rossum E.F.C., Penninx B.W. Depression and obesity: Evidence of shared biological mechanisms. Mol. Psychiatry. 2019;24:18&#x2013;33. doi: 10.1038/s41380-018-0017-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0017-5</ArticleId><ArticleId IdType="pubmed">29453413</ArticleId></ArticleIdList></Reference><Reference><Citation>SayuriYamagata A., Brietzke E., Rosenblat J.D., Kakar R., McIntyre R.S. Medical comorbidity in bipolar disorder: The link with metabolic-inflammatory systems. J. Affect. Disord. 2017;211:99&#x2013;106. doi: 10.1016/j.jad.2016.12.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2016.12.059</ArticleId><ArticleId IdType="pubmed">28107669</ArticleId></ArticleIdList></Reference><Reference><Citation>Salviati M., Valeriani G., Terlizzi S., Maurizi A., Melcore C., Romano G.F., Panico R., Biondi M. The bidirectional relationship between insulin resistance and psychiatric disorders: Considerations for using HOMA-IR index. Clin. Ter. 2013;164:e549&#x2013;e561. doi: 10.7417/CT.2013.1652.</Citation><ArticleIdList><ArticleId IdType="doi">10.7417/CT.2013.1652</ArticleId><ArticleId IdType="pubmed">24424238</ArticleId></ArticleIdList></Reference><Reference><Citation>Starostina E. Comorbidity Between Mental and Physical Disorders. Springer; Cham, Switzerland: 2025. Comorbidity Between Severe Mental Disorders and Metabolic Disease; pp. 181&#x2013;202.</Citation></Reference><Reference><Citation>Regan A.S., Valcourt S.C. Metabolic Syndrome in Bipolar Disorder: Review and Management. Psychiatr. Ann. 2020;50:334&#x2013;339. doi: 10.3928/00485713-20200713-01.</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/00485713-20200713-01</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss F., Brancati G.E., Elefante C., Petrucci A., Gemmellaro T., Lattanzi L., Perugi G. Type 2 diabetes mellitus is associated with manic morbidity in elderly patients with mood disorders. Int. Clin. Psychopharmacol. 2024;39:294&#x2013;304. doi: 10.1097/YIC.0000000000000515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YIC.0000000000000515</ArticleId><ArticleId IdType="pubmed">37824397</ArticleId></ArticleIdList></Reference><Reference><Citation>Maksyutynska K., Stogios N., Prasad F., Gill J., Hamza Z., De R., Smith E., Horta A., Goldstein B.I., Korczak D., et al. Neurocognitive correlates of metabolic dysregulation in individuals with mood disorders: A systematic review and meta-analysis. Psychol. Med. 2024;54:1245&#x2013;1271. doi: 10.1017/S0033291724000345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291724000345</ArticleId><ArticleId IdType="pubmed">38450447</ArticleId></ArticleIdList></Reference><Reference><Citation>Kullmann S., Heni M., Veit R., Ketterer C., Schick F., H&#xe4;ring H.-U., Fritsche A., Preissl H. The obese brain: Association of body mass index and insulin sensitivity with resting state network functional connectivity. Hum. Brain Mapp. 2011;33:1052. doi: 10.1002/hbm.21268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.21268</ArticleId><ArticleId IdType="pmc">PMC6870244</ArticleId><ArticleId IdType="pubmed">21520345</ArticleId></ArticleIdList></Reference><Reference><Citation>Colomer L., Anmella G., Vieta E., Grande I. Physical health in affective disorders: A narrative review of the literature. Rev. Bras. Psiquiatr. 2021;43:621&#x2013;630. doi: 10.1590/1516-4446-2020-1246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1516-4446-2020-1246</ArticleId><ArticleId IdType="pmc">PMC8639004</ArticleId><ArticleId IdType="pubmed">33146344</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones B.D.M., Farooqui S., Kloiber S., Husain M.O., Mulsant B.H., Husain M.I. Targeting Metabolic Dysfunction for the Treatment of Mood Disorders: Review of the Evidence. Life. 2021;11:819. doi: 10.3390/life11080819.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life11080819</ArticleId><ArticleId IdType="pmc">PMC8401631</ArticleId><ArticleId IdType="pubmed">34440563</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan A., Hu F.B. Response to Comment on: Pan et al. Bidirectional Association Between Depression and Metabolic Syndrome: A Systematic Review and Meta-analysis of Epidemiological Studies. Diabetes Care 2012;35:1171&#x2013;1180. Diabetes Care. 2013;36:e28. doi: 10.2337/dc12-1779.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc12-1779</ArticleId><ArticleId IdType="pmc">PMC3329841</ArticleId><ArticleId IdType="pubmed">22517938</ArticleId></ArticleIdList></Reference><Reference><Citation>McElroy S.L., Keck P.E. Metabolic syndrome in bipolar disorder: A review with a focus on bipolar depression. J. Clin. Psychiatry. 2014;75:46&#x2013;61. doi: 10.4088/JCP.13r08634.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.13r08634</ArticleId><ArticleId IdType="pubmed">24502861</ArticleId></ArticleIdList></Reference><Reference><Citation>Vancampfort D., Correll C.U., Galling B., Probst M., De Hert M., Ward P.B., Rosenbaum S., Gaughran F., Lally J., Stubbs B. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: A systematic review and large scale meta-analysis. World Psychiatry Off. J. World Psychiatr. Assoc. WPA. 2016;15:166&#x2013;174. doi: 10.1002/wps.20309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wps.20309</ArticleId><ArticleId IdType="pmc">PMC4911762</ArticleId><ArticleId IdType="pubmed">27265707</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor V., MacQueen G. Associations between bipolar disorder and metabolic syndrome: A review. J. Clin. Psychiatry. 2006;67:1034&#x2013;1041. doi: 10.4088/JCP.v67n0704.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.v67n0704</ArticleId><ArticleId IdType="pubmed">16889445</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira A.L., Martins L.B., Berk M., Bauer M.E. Severe psychiatric disorders and general medical comorbidities: Inflammation-related mechanisms and therapeutic opportunities. Clin. Sci. 2022;136:1257&#x2013;1280. doi: 10.1042/CS20211106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20211106</ArticleId><ArticleId IdType="pubmed">36062418</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu W., Cai X., Zheng C., Qiu S., Ke H., Huang Y. Update on the Relationship Between Depression and Neuroendocrine Metabolism. Front. Neurosci. 2021;15:728810. doi: 10.3389/fnins.2021.728810.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.728810</ArticleId><ArticleId IdType="pmc">PMC8438205</ArticleId><ArticleId IdType="pubmed">34531719</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T.T.L., Chan L.C., Borreginne K., Kale R.P., Hu C., Tye S.J. A review of brain insulin signaling in mood disorders: From biomarker to clinical target. Neurosci. Biobehav. Rev. 2018;92:7&#x2013;15. doi: 10.1016/j.neubiorev.2018.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2018.05.014</ArticleId><ArticleId IdType="pubmed">29758232</ArticleId></ArticleIdList></Reference><Reference><Citation>Correll C.U., Lencz T., Malhotra A.K. Antipsychotic drugs and obesity. Trends Mol. Med. 2011;17:97&#x2013;107. doi: 10.1016/j.molmed.2010.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2010.10.010</ArticleId><ArticleId IdType="pmc">PMC3053585</ArticleId><ArticleId IdType="pubmed">21185230</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheen A.J. Metabolic disorders induced by psychotropic drugs. Ann. Endocrinol. 2023;84:357&#x2013;363. doi: 10.1016/j.ando.2023.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ando.2023.03.006</ArticleId><ArticleId IdType="pubmed">36963753</ArticleId></ArticleIdList></Reference><Reference><Citation>Gp R., Sl K. Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. Pharmacol. Ther. 2010;125:169&#x2013;179. doi: 10.1016/j.pharmthera.2009.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2009.10.010</ArticleId><ArticleId IdType="pubmed">19931306</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong L., Wang H., Yan N., Xu C., Chen Y., Zeng Y., Guo X., Lu J., Hu S. Effect of antipsychotics and mood stabilisers on metabolism in bipolar disorder: A network meta-analysis of randomised-controlled trials. eClinicalMedicine. 2024;71:102581. doi: 10.1016/j.eclinm.2024.102581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2024.102581</ArticleId><ArticleId IdType="pmc">PMC11015341</ArticleId><ArticleId IdType="pubmed">38618207</ArticleId></ArticleIdList></Reference><Reference><Citation>Cermolacce M., Belzeaux R., Adida M., Azorin J.-M. Affective disorders: Endocrine and metabolic comorbidities. L&#x2019;Encephale. 2014;40((Suppl. 3)):S33&#x2013;S39. doi: 10.1016/S0013-7006(14)70129-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0013-7006(14)70129-0</ArticleId><ArticleId IdType="pubmed">25550238</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazereel V., Detraux J., Vancampfort D., Van Winkel R., De Hert M. Impact of Psychotropic Medication Effects on Obesity and the Metabolic Syndrome in People With Serious Mental Illness. Front. Endocrinol. 2020;11:573479. doi: 10.3389/fendo.2020.573479.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2020.573479</ArticleId><ArticleId IdType="pmc">PMC7581736</ArticleId><ArticleId IdType="pubmed">33162935</ArticleId></ArticleIdList></Reference><Reference><Citation>Filakovi&#x107; P., Eri&#x107; A.P., Radanovi&#x107;-Grguri&#x107; L. Metabolic syndrome and psychotropic medications.  [(accessed on 1 August 2025)];Med. Glas. Off. Publ. Med. Assoc. Zenica-Doboj Cant. Bosnia Herzeg. 2012 9:180&#x2013;188. Available online:  https://pubmed.ncbi.nlm.nih.gov/22926348/</Citation><ArticleIdList><ArticleId IdType="pubmed">22926348</ArticleId></ArticleIdList></Reference><Reference><Citation>De Hert M., Detraux J., van Winkel R., Yu W., Correll C.U. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat. Rev. Endocrinol. 2011;8:114&#x2013;126. doi: 10.1038/nrendo.2011.156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2011.156</ArticleId><ArticleId IdType="pubmed">22009159</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuen J.W.Y., Kim D.D., Procyshyn R.M., Panenka W.J., Honer W.G., Barr A.M. A Focused Review of the Metabolic Side-Effects of Clozapine. Front. Endocrinol. 2021;12:609240. doi: 10.3389/fendo.2021.609240.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2021.609240</ArticleId><ArticleId IdType="pmc">PMC7947876</ArticleId><ArticleId IdType="pubmed">33716966</ArticleId></ArticleIdList></Reference><Reference><Citation>Gahr M. Metabolic adverse drug reactions related to psychotropic drugs. Fortschr. Neurol. Psychiatr. 2025;93:95&#x2013;103. doi: 10.1055/a-2405-5087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-2405-5087</ArticleId><ArticleId IdType="pubmed">39313203</ArticleId></ArticleIdList></Reference><Reference><Citation>Serretti A., Mandelli L. Antidepressants and body weight: A comprehensive review and meta-analysis. J. Clin. Psychiatry. 2010;71:979. doi: 10.4088/JCP.09r05346blu.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.09r05346blu</ArticleId><ArticleId IdType="pubmed">21062615</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee S., Im S.-S. Decoding Health: Exploring Essential Biomarkers Linked to Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus. Biomedicines. 2025;13:359. doi: 10.3390/biomedicines13020359.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines13020359</ArticleId><ArticleId IdType="pmc">PMC11853123</ArticleId><ArticleId IdType="pubmed">40002771</ArticleId></ArticleIdList></Reference><Reference><Citation>Qassab M.A., Mneimneh M., Jradi A., Derbas B., Dabboussi D., Baini J.K., Katrib N., Chaarani N., Attieh P., Kanaan A., et al. The Expanding Role of GLP-1 Receptor Agonists: Advancing Clinical Outcomes in Metabolic and Mental Health. Curr. Issues Mol. Biol. 2025;47:285. doi: 10.3390/cimb47040285.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cimb47040285</ArticleId><ArticleId IdType="pmc">PMC12025658</ArticleId><ArticleId IdType="pubmed">40699685</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Fu X., Liu Y., Wang T., Zhao X., Cui R., Yang W. Exploring the Effect and Mechanism of Liraglutide in Treating Depression Based on Network Pharmacology and Experimental Analysis. J. Cell Mol. Med. 2025;29:e70630. doi: 10.1111/jcmm.70630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.70630</ArticleId><ArticleId IdType="pmc">PMC12133450</ArticleId><ArticleId IdType="pubmed">40461955</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Zhao P., Wang W., Guo L., Pan Q. The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. Am. J. Geriatr. Psychiatry Off. J. Am. Assoc. Geriatr. Psychiatry. 2024;32:117&#x2013;127. doi: 10.1016/j.jagp.2023.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jagp.2023.08.010</ArticleId><ArticleId IdType="pubmed">37684186</ArticleId></ArticleIdList></Reference><Reference><Citation>Monney M., Jornayvaz F., Gariani K. GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes. Diabetes Metab. 2023;49:101470. doi: 10.1016/j.diabet.2023.101470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabet.2023.101470</ArticleId><ArticleId IdType="pubmed">37657738</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabahizi A., Wallace B., Lieu L., Chau D., Dong Y., Hwang E., Williams K.W. Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics. Br. J. Pharmacol. 2022;179:600&#x2013;624. doi: 10.1111/bph.15682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15682</ArticleId><ArticleId IdType="pmc">PMC8820188</ArticleId><ArticleId IdType="pubmed">34519026</ArticleId></ArticleIdList></Reference><Reference><Citation>Ress C., Tschoner A., Kaser S., Ebenbichler C.F. Psychotropic drugs and diabetes. Wien. Med. Wochenschr. 2011;161:531&#x2013;542. doi: 10.1007/s10354-011-0004-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10354-011-0004-9</ArticleId><ArticleId IdType="pubmed">21792529</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolger A., Verdolini N., Agius M. Can metabolic side effects of antipsychotics be reversed by lifestyle changes? Psychiatr. Danub. 2014;26((Suppl. 1)):330&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">25413560</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopp K.O., Glotfelty E.J., Li Y., Greig N.H. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment. Pharmacol. Res. 2022;186:106550. doi: 10.1016/j.phrs.2022.106550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2022.106550</ArticleId><ArticleId IdType="pmc">PMC9712272</ArticleId><ArticleId IdType="pubmed">36372278</ArticleId></ArticleIdList></Reference><Reference><Citation>Nousen E.K., Franco J.G., Sullivan E.L. Unraveling the mechanisms responsible for the comorbidity between metabolic syndrome and mental health disorders. Neuroendocrinology. 2013;98:254&#x2013;266. doi: 10.1159/000355632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000355632</ArticleId><ArticleId IdType="pmc">PMC4121390</ArticleId><ArticleId IdType="pubmed">24080959</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggio L.L., Drucker D.J. Glucagon-like peptide-1 receptors in the brain: Controlling food intake and body weight. J. Clin. Investig. 2014;124:4223&#x2013;4226. doi: 10.1172/JCI78371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI78371</ArticleId><ArticleId IdType="pmc">PMC4191040</ArticleId><ArticleId IdType="pubmed">25202976</ArticleId></ArticleIdList></Reference><Reference><Citation>Drucker D.J. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27:740&#x2013;756. doi: 10.1016/j.cmet.2018.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2018.03.001</ArticleId><ArticleId IdType="pubmed">29617641</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezin J., B&#xe9;nard-Laribi&#xe8;re A., Hucteau E., Tournier M., Montastruc F., Pariente A., Faillie J.-L. Suicide and suicide attempt in users of GLP-1 receptor agonists: A nationwide case-time-control study. eClinicalMedicine. 2025;80:103029. doi: 10.1016/j.eclinm.2024.103029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2024.103029</ArticleId><ArticleId IdType="pmc">PMC11751538</ArticleId><ArticleId IdType="pubmed">39844933</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansur R.B., Ahmed J., Cha D.S., Woldeyohannes H.O., Subramaniapillai M., Lovshin J., Lee J.G., Lee J.-H., Brietzke E., Reininghaus E.Z., et al. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study. J. Affect. Disord. 2017;207:114&#x2013;120. doi: 10.1016/j.jad.2016.09.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2016.09.056</ArticleId><ArticleId IdType="pubmed">27721184</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda P., S&#xf6;derling J., Wintzell V., Svanstr&#xf6;m H., Pazzagli L., Eliasson B., Melbye M., Hviid A., Pasternak B. GLP-1 Receptor Agonist Use and Risk of Suicide Death. JAMA Intern. Med. 2024;184:1301&#x2013;1312. doi: 10.1001/jamainternmed.2024.4369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2024.4369</ArticleId><ArticleId IdType="pmc">PMC11372654</ArticleId><ArticleId IdType="pubmed">39226030</ArticleId></ArticleIdList></Reference><Reference><Citation>Farr O.M., Sofopoulos M., Tsoukas M.A., Dincer F., Thakkar B., Sahin-Efe A., Filippaios A., Bowers J., Srnka A., Gavrieli A., et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: A crossover, randomised, placebo-controlled trial. Diabetologia. 2016;59:954&#x2013;965. doi: 10.1007/s00125-016-3874-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-016-3874-y</ArticleId><ArticleId IdType="pmc">PMC4826792</ArticleId><ArticleId IdType="pubmed">26831302</ArticleId></ArticleIdList></Reference><Reference><Citation>van Bloemendaal L., IJzerman R.G., ten Kulve J.S., Barkhof F., Konrad R.J., Drent M.L., Veltman D.J., Diamant M. GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans. Diabetes. 2014;63:4186&#x2013;4196. doi: 10.2337/db14-0849.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db14-0849</ArticleId><ArticleId IdType="pubmed">25071023</ArticleId></ArticleIdList></Reference><Reference><Citation>Coveleskie K., Kilpatrick L.A., Gupta A., Stains J., Connolly L., Labus J.S., Sanmiguel C., Mayer E.A. The effect of the GLP-1 analogue Exenatide on functional connectivity within an NTS-based network in women with and without obesity. Obes. Sci. Pract. 2017;3:434&#x2013;445. doi: 10.1002/osp4.124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/osp4.124</ArticleId><ArticleId IdType="pmc">PMC5729499</ArticleId><ArticleId IdType="pubmed">29259802</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Zhang L., Li L., H&#xf6;lscher C. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson&#x2019;s disease mouse model. Neuropeptides. 2018;71:70&#x2013;80. doi: 10.1016/j.npep.2018.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.npep.2018.07.003</ArticleId><ArticleId IdType="pubmed">30017231</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderberg R.H., Richard J.E., Hansson C., Nissbrandt H., Bergquist F., Skibicka K.P. GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. Psychoneuroendocrinology. 2016;65:54&#x2013;66. doi: 10.1016/j.psyneuen.2015.11.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psyneuen.2015.11.021</ArticleId><ArticleId IdType="pubmed">26724568</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson S.L., Shirazi R.H., Hansson C., Bergquist F., Nissbrandt H., Skibicka K.P. The Glucagon-Like Peptide 1 (GLP-1) Analogue, Exendin-4, Decreases the Rewarding Value of Food: A New Role for Mesolimbic GLP-1 Receptors. J. Neurosci. 2012;32:4812&#x2013;4820. doi: 10.1523/JNEUROSCI.6326-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6326-11.2012</ArticleId><ArticleId IdType="pmc">PMC6620919</ArticleId><ArticleId IdType="pubmed">22492036</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R.-F., Xue G.-F., H&#xf6;lscher C., Tian M.-J., Feng P., Zheng J.-Y., Li D.-F. Post-treatment with the GLP-1 analogue liraglutide alleviate chronic inflammation and mitochondrial stress induced by Status epilepticus. Epilepsy Res. 2018;142:45&#x2013;52. doi: 10.1016/j.eplepsyres.2018.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eplepsyres.2018.03.009</ArticleId><ArticleId IdType="pubmed">29549796</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruber J., Hanssen R., Qubad M., Bouzouina A., Schack V., Sochor H., Schiweck C., Aichholzer M., Matura S., Slattery D.A., et al. Impact of insulin and insulin resistance on brain dopamine signalling and reward processing&#x2014;An underexplored mechanism in the pathophysiology of depression? Neurosci. Biobehav. Rev. 2023;149:105179. doi: 10.1016/j.neubiorev.2023.105179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2023.105179</ArticleId><ArticleId IdType="pubmed">37059404</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Q., Wang L., Liu X.-X., An Z.-G., Luo X., Zhang L.-L., Yan P., Jin L., Cai R., Yi Q.-Z. GLP-1 plays a protective role in hippocampal neuronal cells by activating cAMP-CREB-BDNF signaling pathway against CORT+HG-induced toxicity. Heliyon. 2023;9:e18491. doi: 10.1016/j.heliyon.2023.e18491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e18491</ArticleId><ArticleId IdType="pmc">PMC10412908</ArticleId><ArticleId IdType="pubmed">37576283</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Huang Q., Feng J., Xiao Z., Zhang X., Zhao L. GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-&#x3ba;B signalling pathway. J. Int. Med. Res. 2021;49:0300060521992981. doi: 10.1177/0300060521992981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0300060521992981</ArticleId><ArticleId IdType="pmc">PMC7917887</ArticleId><ArticleId IdType="pubmed">33641439</ArticleId></ArticleIdList></Reference><Reference><Citation>Zitman-Gal T., Einbinder Y., Ohana M., Katzav A., Kartawy A., Benchetrit S. Effect of liraglutide on the Janus kinase/signal transducer and transcription activator (JAK/STAT) pathway in diabetic kidney disease in db/db mice and in cultured endothelial cells. J. Diabetes. 2019;11:656&#x2013;664. doi: 10.1111/1753-0407.12891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1753-0407.12891</ArticleId><ArticleId IdType="pubmed">30575282</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Lin Y., Wang S., Zhang L., Guo L. GLP-1 Inhibits High-Glucose-Induced Oxidative Injury of Vascular Endothelial Cells. Sci. Rep. 2017;7:8008. doi: 10.1038/s41598-017-06712-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-06712-z</ArticleId><ArticleId IdType="pmc">PMC5555999</ArticleId><ArticleId IdType="pubmed">28808291</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Li Z., Cao X., Ma H., White P.F., Xu X., Jiang Y., Sun X., Cui Y. Exendin-4 improves behaviorial deficits via GLP-1/GLP-1R signaling following partial hepatectomy. Brain Res. 2019;1706:116&#x2013;124. doi: 10.1016/j.brainres.2018.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.11.007</ArticleId><ArticleId IdType="pubmed">30408479</ArticleId></ArticleIdList></Reference><Reference><Citation>Sa&#x11f;lam C., Turan &#x130;., &#xd6;za&#xe7;mak H.S. The effect of glucagon like peptide-1 receptor agonist on behavioral despair and anxiety-like behavior in ovariectomized rats: Modulation of BDNF/CREB, Nrf2 and lipocalin 2. Behav. Brain Res. 2022;435:114053. doi: 10.1016/j.bbr.2022.114053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2022.114053</ArticleId><ArticleId IdType="pubmed">35961539</ArticleId></ArticleIdList></Reference><Reference><Citation>de Paiva I.H.R., da Silva R.S., Mendon&#xe7;a I.P., de Souza J.R.B., Peixoto C.A. Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis. J. Neuroimmune Pharmacol. Off. J. Soc. NeuroImmune Pharmacol. 2024;19:36. doi: 10.1007/s11481-024-10142-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11481-024-10142-w</ArticleId><ArticleId IdType="pubmed">39042202</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozzi M., Mazhar F., Peeters G.G.A.M., Vantaggiato C., Nobile M., Clementi E., Radice S., Carnovale C. A systematic review of the antidepressant effects of glucagon-like peptide 1 (GLP-1) functional agonists: Further link between metabolism and psychopathology: Special Section on &#x201c;Translational and Neuroscience Studies in Affective Disorders&#x201d;. Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders. J. Affect. Disord. 2019;257:774&#x2013;778. doi: 10.1016/j.jad.2019.05.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2019.05.044</ArticleId><ArticleId IdType="pubmed">31153593</ArticleId></ArticleIdList></Reference><Reference><Citation>Wakabayashi K.T., Baindur A.N., Feja M., Suarez M., Chen K., Bernosky-Smith K., Bass C.E. Synthetic exendin-4 disrupts responding to reward predictive incentive cues in male rats. Front. Behav. Neurosci. 2024;18:1363497. doi: 10.3389/fnbeh.2024.1363497.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnbeh.2024.1363497</ArticleId><ArticleId IdType="pmc">PMC10976559</ArticleId><ArticleId IdType="pubmed">38549620</ArticleId></ArticleIdList></Reference><Reference><Citation>Deden L.N., Booij J., Grandjean J., Homberg J.R., Hazebroek E.J., Gotthardt M., Boss M. Brain Imaging of the GLP-1 Receptor in Obesity Using 68Ga-NODAGA-Exendin-4 PET. Brain Sci. 2021;11:1647. doi: 10.3390/brainsci11121647.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11121647</ArticleId><ArticleId IdType="pmc">PMC8699257</ArticleId><ArticleId IdType="pubmed">34942949</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai C.-Y., Lu H.-C., Chou Y.-H., Liu P.-Y., Chen H.-Y., Huang M.-C., Lin C.-H., Tsai C.-N. Gut Microbial Signatures for Glycemic Responses of GLP-1 Receptor Agonists in Type 2 Diabetic Patients: A Pilot Study. Front. Endocrinol. 2022;12:814770. doi: 10.3389/fendo.2021.814770.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2021.814770</ArticleId><ArticleId IdType="pmc">PMC8793908</ArticleId><ArticleId IdType="pubmed">35095773</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng J., Teng Z., Yang Y., Liu J., Chen S. Effects of semaglutide on gut microbiota, cognitive function and inflammation in obese mice. PeerJ. 2024;12:e17891. doi: 10.7717/peerj.17891.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.17891</ArticleId><ArticleId IdType="pmc">PMC11326427</ArticleId><ArticleId IdType="pubmed">39148685</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman S., Alvares D., Adeli K. GLP-1 attenuates intestinal fat absorption and chylomicron production via vagal afferent nerves originating in the portal vein. Mol. Metab. 2022;65:101590. doi: 10.1016/j.molmet.2022.101590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmet.2022.101590</ArticleId><ArticleId IdType="pmc">PMC9486018</ArticleId><ArticleId IdType="pubmed">36067913</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki Y., Sendo M., Dezaki K., Hira T., Sato T., Nakata M., Goswami C., Aoki R., Arai T., Kumari P., et al. GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose. Nat. Commun. 2018;9:113. doi: 10.1038/s41467-017-02488-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02488-y</ArticleId><ArticleId IdType="pmc">PMC5760716</ArticleId><ArticleId IdType="pubmed">29317623</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindqvist A., Shcherbina L., Fischer A.-H.T., Wierup N. Ghrelin Is a Regulator of Glucagon-Like Peptide 1 Secretion and Transcription in Mice. Front. Endocrinol. 2017;8:135. doi: 10.3389/fendo.2017.00135.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2017.00135</ArticleId><ArticleId IdType="pmc">PMC5475379</ArticleId><ArticleId IdType="pubmed">28674521</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang J., Liu F., Zhang B., Dong K., Lu M., Jiang R., Xu Y., Diao L., Zhao J., Tang H. Liraglutide-induced structural modulation of the gut microbiota in patients with type 2 diabetes mellitus. PeerJ. 2021;9:e11128. doi: 10.7717/peerj.11128.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.11128</ArticleId><ArticleId IdType="pmc">PMC8019531</ArticleId><ArticleId IdType="pubmed">33850659</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng N., Cutts E.J., Lopez C.B., Kaur S., Duran M., Virkus S.A., Hardaway J.A. Anatomical and Functional Characterization of Central Amygdala Glucagon-Like Peptide 1 Receptor Expressing Neurons. Front. Behav. Neurosci. 2021;15:724030. doi: 10.3389/fnbeh.2021.724030.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnbeh.2021.724030</ArticleId><ArticleId IdType="pmc">PMC8739476</ArticleId><ArticleId IdType="pubmed">35002645</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida O.P. Risk of depression and dementia among individuals treated with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. Curr. Opin. Psychiatry. 2025;38:368&#x2013;375. doi: 10.1097/YCO.0000000000001001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YCO.0000000000001001</ArticleId><ArticleId IdType="pubmed">40009763</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill H., Lieberman J., DiVincenzo J., Rodrigues N., Mansur R., McKenzie A., Phan L., Rosenblat J., McIntyre R. Evaluating the Use of Glucagon-Like Peptide 1 for the Treatment of Cognitive Dysfunction in Individuals with Mood Disorders. Curr. Treat. Options Psychiatry. 2022;9:331&#x2013;345. doi: 10.1007/s40501-022-00281-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40501-022-00281-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali M., Ahmed A., Khan B.A., Shah S.T., Naveed S., Ashraf N. Efficacy of GLP-1 Agonists in Psychiatric Illnesses: A Scoping Review. Prim. Care Companion CNS Disord. 2025;27:24nr03828. doi: 10.4088/PCC.24nr03828.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/PCC.24nr03828</ArticleId><ArticleId IdType="pubmed">40505607</ArticleId></ArticleIdList></Reference><Reference><Citation>VI N.B., Tressler E.H., Vendruscolo L.F., Leggio L., Farokhnia M. IUPHAR review&#x2014;Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target. Pharmacol. Res. 2024;207:107312. doi: 10.1016/j.phrs.2024.107312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2024.107312</ArticleId><ArticleId IdType="pmc">PMC11467891</ArticleId><ArticleId IdType="pubmed">39032839</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang L., Peng Y. Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study. Int. J. Mol. Sci. 2025;26:2741. doi: 10.3390/ijms26062741.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms26062741</ArticleId><ArticleId IdType="pmc">PMC11942543</ArticleId><ArticleId IdType="pubmed">40141382</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobaiqy M., Elkout H. Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: A pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database. Int. J. Clin. Pharm. 2024;46:488&#x2013;495. doi: 10.1007/s11096-023-01694-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11096-023-01694-7</ArticleId><ArticleId IdType="pmc">PMC10960895</ArticleId><ArticleId IdType="pubmed">38265519</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.A., Yoo H.J. Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning. Diabetes Metab. J. 2025;49:525&#x2013;541. doi: 10.4093/dmj.2025.0242.</Citation><ArticleIdList><ArticleId IdType="doi">10.4093/dmj.2025.0242</ArticleId><ArticleId IdType="pmc">PMC12270588</ArticleId><ArticleId IdType="pubmed">40631457</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilly-Harrington N.A., Himes S.M., Lauretti-Robbins J., Sogg S. One Size Does Not Fit All: Special Considerations for Behavioral Health Providers Treating Patients Using GLP-1RA Medications for Obesity. Cogn. Behav. Pract. :2025. doi: 10.1016/j.cbpra.2025.02.004. in press .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbpra.2025.02.004</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>